fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Sandoz Efavirenz/Emtricitabine/Tenofovir (02484676). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Efavirenz/tenofovir disoproxil fumarate/emtricitabine

All products: general benefit

Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · 600 mg/300 mg/200 mg · tablet

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 Manufacturer: Apotex Inc.; listing date 2018-10-31 Health Canada: Marketed since 2018-09-04 · brand APO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EFAVIRENZ 600 MG, EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Apotex inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Apo-Efavirenz-Emtricitabine-Tenofovir: Formulary list price $11.33 per unit (the source does not state the unit; exact figure $11.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02468247)

Source record
DIN 02468247: Apo-Efavirenz-Emtricitabine-Tenofovir Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id APX Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $11.3300; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02468247 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95665
Interchangeable products
Atripla · DIN 02300699 · $11.3300 Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300 Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300 Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300 PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300 Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · $11.3300
Shortage status: resolved shortage (ended September 5, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468247
Shortage record checked October 6, 2026

Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · 600 mg/300 mg/200 mg · tablet

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 Manufacturer: Auro Pharma Inc.; listing date 2020-05-29 Health Canada: Marketed since 2020-03-18 · brand AURO-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EFAVIRENZ 600 MG, EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Efavirenz-Emtricitabine-Tenofovir: Formulary list price $11.33 per unit (the source does not state the unit; exact figure $11.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02478404)

Source record
DIN 02478404: Auro-Efavirenz-Emtricitabine-Tenofovir Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id AUR Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $11.3300; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02478404 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96916
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300 Atripla · DIN 02300699 · $11.3300 Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300 Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300 PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300 Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · $11.3300
Shortage status: resolved shortage (ended December 2, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02478404
Shortage record checked October 6, 2026

Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · 600 mg/300 mg/200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 Manufacturer: Jamp Pharma Corporation; listing date 2023-01-31 Health Canada: Marketed since 2022-12-14 · brand JAMP EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ, J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EMTRICITABINE 200 MG, EFAVIRENZ 600 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Jamp pharma corporation · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Jamp Efavirenz/Emtricitabine/Tenofovir: Formulary list price $11.33 per unit (the source does not state the unit; exact figure $11.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519461)

Source record
DIN 02519461: Jamp Efavirenz/Emtricitabine/Tenofovir Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id JPC Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $11.3300; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519461 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100873
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300 Atripla · DIN 02300699 · $11.3300 Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300 Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300 PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300 Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · $11.3300
Shortage status: active shortage (reported March 12, 2026, estimated to end June 30, 2027, last updated September 21, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519461
Shortage record checked October 6, 2026

Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · 600 mg/300 mg/200 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2017-09-28 Health Canada: Marketed since 2017-07-31 · brand MYLAN-EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ, J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EFAVIRENZ 600 MG, EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mylan-Efavirenz/Emtricitabine/Tenofovir: Formulary list price $11.33 per unit (the source does not state the unit; exact figure $11.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02461412)

Source record
DIN 02461412: Mylan-Efavirenz/Emtricitabine/Tenofovir Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id MYL Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $11.3300; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02461412 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94902
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300 Atripla · DIN 02300699 · $11.3300 Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300 Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300 PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300 Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · $11.3300
Shortage status: active shortage (reported October 7, 2024, last updated April 14, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461412
Shortage record checked October 6, 2026

Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · 600 mg/300 mg/200 mg · tablet

General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 Manufacturer: Teva Canada Limited; listing date 2017-09-28 Health Canada: Marketed since 2017-07-26 · brand TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EFAVIRENZ 600 MG, EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Efavirenz/Emtricitabine/Tenofovir: Formulary list price $11.33 per unit (the source does not state the unit; exact figure $11.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02393549)

Source record
DIN 02393549: Teva-Efavirenz/Emtricitabine/Tenofovir Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id TEV Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $11.3300; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02393549 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87876
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300 Atripla · DIN 02300699 · $11.3300 Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300 Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300 Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300 PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300
Shortage status: active shortage (reported January 20, 2025, last updated January 23, 2025); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393549
Shortage record checked October 6, 2026

PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · 600 mg/300 mg/200 mg · tablet

General benefitDormant since July 31, 2025 · checked November 18, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 Manufacturer: Pharmascience Inc.; listing date 2020-02-28 Health Canada: Dormant since 2025-07-31 · brand PMS-EFAVIRENZ-EMTRICITABINE-TENOFOVIR · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EFAVIRENZ 600 MG, EMTRICITABINE 200 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

PMS-Efavirenz-Emtricitabine-Tenofovir: Formulary list price $11.33 per unit (the source does not state the unit; exact figure $11.3300). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02487284)

Source record
DIN 02487284: PMS-Efavirenz-Emtricitabine-Tenofovir Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id PMS Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $11.3300; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02487284 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97744
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300 Atripla · DIN 02300699 · $11.3300 Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300 Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300 Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300 Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · $11.3300
Shortage status: resolved shortage (ended October 21, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02487284
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2025 — choose a marketed DIN from the same-category list.

Atripla · DIN 02300699 · 600 mg/300 mg/200 mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-22 — choose a marketed DIN from the same-category list.Discontinued December 22, 2021 · checked October 5, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-12-22 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-12-22 — choose a marketed DIN from the same-category list.
Patient paysODB senior: $100/program-year deductible • Then up to $6.11 per prescription Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
1 brand, same coverage
Atripla · DIN 02300699 Manufacturer: Bristol Myers Squibb Canada Inc; listing date 2008-08-28 Health Canada: Cancelled post market since 2021-12-22 · brand ATRIPLA · ATC J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ, J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ · form Tablet · route Oral · ingredients EMTRICITABINE 200 MG, EFAVIRENZ 600 MG, TENOFOVIR DISOPROXIL FUMARATE 300 MG · company Gilead sciences, llc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02300699)

Source record
DIN 02300699: Atripla Raw flags: sec3=Y Item: 081800103; group id 80; item number 0148; lccId None; manufacturer id BQU Source form: Tab; strength: 600mg/300mg/200mg Recorded listing: General benefit Source prices (unrounded): $45.3200; ministry $11.3300 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02300699 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78602
Interchangeable products
Apo-Efavirenz-Emtricitabine-Tenofovir · DIN 02468247 · $11.3300 Auro-Efavirenz-Emtricitabine-Tenofovir · DIN 02478404 · $11.3300 Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 · $11.3300 Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 · $11.3300 PMS-Efavirenz-Emtricitabine-Tenofovir · DIN 02487284 · $11.3300 Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 · $11.3300
Shortage status: discontinued (December 31, 2021, reported by GILEAD SCIENCES, LLC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02300699
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 22, 2021 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (J05AR): coverage varies; not interchangeable

  • Abacavir + lamivudine + zidovudine (Trizivir): general benefit
  • Abacavir + lamivudine (Kivexa): general benefit
  • Bictegravir + emtricitabine + tenofovir alafenamide hemifumarate (Biktarvy): general benefit
  • Cabotegravir + rilpivirine (Cabenuva): general benefit
  • Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil (Stribild): general benefit
  • Cobicistat + darunavir (Prezcobix): general benefit

48 more in the class list below

Other drugs in the same formulary class (08:18 Antivirals) and how they are covered

Matched class: 08:18 Antivirals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ABACAVIR & LAMIVUDINE & ZIDOVUDINE, ABACAVIR SULFATE, ABACAVIR SULFATE & LAMIVUDINE, BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE, CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, DARUNAVIR & COBICISTAT, DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, DELAVIRDINE MESYLATE, DOLUTEGRAVIR, DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE, DOLUTEGRAVIR & RILPIVIRINE, DOLUTEGRAVIR SODIUM/LAMIVUDINE, DORAVIRINE, DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE, ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR ALAFENAMIDE HEMIFUMARATE, EMTRICITABINE & RILPIVIRINE HCL & TENOFOVIR DISOPROXIL, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, ETRAVIRINE, FOSAMPRENAVIR CALCIUM, GANCICLOVIR SODIUM, LAMIVUDINE & ZIDOVUDINE, LOPINAVIR & RITONAVIR, MARAVIROC, NELFINAVIR MESYLATE, RALTEGRAVIR POTASSIUM, RILPIVIRINE HYDROCHLORIDE, RITONAVIR Some products covered without a code (check the product listing): ACYCLOVIR, ATAZANAVIR SULFATE, DARUNAVIR, EFAVIRENZ, LAMIVUDINE, NEVIRAPINE, VALACYCLOVIR 08:18 Antivirals

ABACAVIR & LAMIVUDINE & ZIDOVUDINE

· 2 products · General benefit · strengths: 300mg & 150mg & 300mg · Tab

ABACAVIR SULFATE & LAMIVUDINE

· 7 products · General benefit · strengths: 600mg & 300mg · Tab

BICTEGRAVIR SODIUM/EMTRICITABINE/TENOFOVIR ALAFENAMIDE HEMIFUMARATE

· 1 products · General benefit · strengths: 50mg & 200mg & 25mg · Tab

CABOTEGRAVIR & RILPIVIRINE

· 2 products · General benefit · strengths: 200mg/mL & 300mg/mL · Inj Sol-2mL Kit, Inj Sol-3mL Kit

COBICISTAT & ELVITEGRAVIR & EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 300mg · Tab

DARUNAVIR & COBICISTAT

· 1 products · General benefit · strengths: 800mg & 150mg · Tab

DARUNAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE

· 1 products · General benefit · strengths: 800mg & 150mg & 200mg & 10mg · Tab

DOLUTEGRAVIR & ABACAVIR & LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 600mg & 300mg · Tab

DOLUTEGRAVIR & RILPIVIRINE

· 1 products · General benefit · strengths: 50mg & 25mg · Tab

DOLUTEGRAVIR SODIUM/LAMIVUDINE

· 1 products · General benefit · strengths: 50mg & 300mg · Tab

DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE

· 1 products · General benefit · strengths: 100mg & 300mg & 300mg · Tab

ELVITEGRAVIR & COBICISTAT & EMTRICITABINE & TENOFOVIR ALAFENAMIDE

· 1 products · General benefit · strengths: 150mg & 150mg & 200mg & 10mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:18 and 42 more
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: hiv-1 infection
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: CABOTEGRAVIR, CABOTEGRAVIR & RILPIVIRINE, DORAVIRINE, EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE, LOPINAVIR & RITONAVIR, RALTEGRAVIR POTASSIUM CABOTEGRAVIR · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080949.PDF; date 2025-06-30; DIN 02497204; fetched 2026-09-10 Product monograph CABOTEGRAVIR & RILPIVIRINE · General benefit 1 Indications VOCABRIA (cabotegravir tablets) is indicated, in combination with EDURANT (rilpivirine tablets), as a complete regimen for short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in patients, at least 12 years of age and weighing at least 35 kg, who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL) as: • an oral lead-in to assess tolerability of cabotegravir prior to initiating CABENUVA • oral bridging therapy for missed CABENUVA injections CABENUVA (cabotegravir and rilpivirine extended release injectable suspensions) is indicated: • as a complete regimen for the treatment of HIV-1 infection in patients, at least 12 years of age and weighing at least 35 kg, to replace the current antiretroviral regimen in patients who are virologically stable and suppressed (HIV-1 RNA less than 50 copies/mL). 1.1 Pediatrics Pediatrics (≥ 12 and < 18 years of age): the use of VOCABRIA and CABENUVA in adolescent patients 12 years of age and older and weighing at least 35 kg is supported by the interim safety and pharmacokinetic data of an ongoing phase 1/2 open-label, non-comparative study in which oral and injectable cabotegravir or oral and injectable rilpivirine, each as a single agent, was administered in combination with other antiretroviral agents, and also by the pharmacokinetic data from studies with VOCABRIA, CABENUVA and oral and injectable rilpivirine use in adults (see 8.2.1 Clinical Trial Adverse Reactions-Pediatrics, 10.3 Pharmacokinetics, and 14 CLINICAL TRIALS; oral rilpivirine use refers to the EDURANT product monograph). PM: https://pdf.hres.ca/dpd_pm/00080951.PDF; date 2025-06-30; DIN 02497220; fetched 2026-09-10 Product monograph DARUNAVIR · Listed, not a benefit (2), General benefit (6) 1 INDICATIONS Auro-Darunavir (darunavir), co-administered with 100 mg ritonavir, and with other antiretroviral agents, is indicated for the treatment of HIV-1 infection in patients ≥ 40 kg. PM: https://pdf.hres.ca/dpd_pm/00073833.PDF; date December 7, 2023; DIN 02486121; fetched 2026-09-10 Product monograph DORAVIRINE · General benefit 1 Indications PIFELTRO® (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at least 35kg without past or present evidence of viral resistance to doravirine. 1.1 Pediatrics Pediatrics ( 12 to < 18 years of age): The safety and efficacy of PIFELTRO® in pediatric patients  12 years of age and weighing at least 35 kg receiving doravirine 100 mg once daily has been established (see 8.2.1 Clinical Trial Adverse Reactions – Pediatrics and 14 Clinical Trials). PM: https://pdf.hres.ca/dpd_pm/00081853.PDF; date not captured; DIN 02481545; fetched 2026-09-10 Product monograph EFAVIRENZ · Listed, not a benefit (1), General benefit (4) INDICATIONS AND CLINICAL USE Mylan-Efavirenz (efavirenz) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00076879.PDF; date AUG 29, 2024; DIN 02381524; fetched 2026-09-10 Product monograph EMTRICITABINE & TENOFOVIR DISOPROXIL FUMARATE · General benefit INDICATIONS AND CLINICAL USE Treatment of HIV-1 Infection TRUVADA is indicated in combination with other antiretroviral agents (such as non- nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. PM: https://pdf.hres.ca/dpd_pm/00046237.PDF; date July 5, 2018; DIN 02274906; fetched 2026-09-10 Product monograph LOPINAVIR & RITONAVIR · General benefit Indications KALETRA (lopinavir/ritonavir) is indicated in combination with other antiretroviral agents when therapy is warranted for the treatment of HIV-1 infection. PM: https://pdf.hres.ca/dpd_pm/00085373.PDF; date 2026-07-14; DIN 02243644; fetched 2026-09-10 Product monograph NEVIRAPINE · Listed, not a benefit (2), General benefit (5) INDICATIONS AND CLINICAL USE AURO-NEVIRAPINE (nevirapine) is indicated as an alternative for:  treatment of HIV-1 infection in combination with other antiretroviral agents. PM: https://pdf.hres.ca/dpd_pm/00058912.PDF; date not captured; DIN 02318601; fetched 2026-09-10 Product monograph RALTEGRAVIR POTASSIUM · General benefit 1 INDICATIONS Adults ISENTRESS® and ISENTRESS HD® (raltegravir) are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. 1.1 Pediatrics Pediatrics (2 - 18 years of age and weighing at least 7kg): ISENTRESS® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in children and adolescents 2 years of age and older with body weight at least 7 kg. PM: https://pdf.hres.ca/dpd_pm/00073112.PDF; date November 9, 2007; DIN 02301881; fetched 2026-09-10 Product monograph TENOFOVIR DISOPROXIL · Limited Use, codes 517, 518, 519, 520, 521, 522 INDICATIONS AND CLINICAL USE HIV-1 Infection VIREAD (tenofovir disoproxil fumarate [TDF]) is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00045932.PDF; date June 13, 2018; DIN 02247128; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR (efavirenz [EFV]/emtricitabine [FTC]/tenofovir disoproxil fumarate [TDF]) is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. (see CLINICAL TRIALS, Description of Clinical Studies and ADVERSE REACTIONS). Geriatrics (>65 years of age): Clinical studies of the components of TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Pediatrics (<18 years of age): Safety and effectiveness in pediatric patients have not been established. TEVA- EFAVIRENZ/EMTRICITABINE/TENOFOVIR is not recommended for pediatric administration. https://pdf.hres.ca/dpd_pm/00056758.PDF PM date: June 1, 2020 Source product: TEVA-EFAVIRENZ/EMTRICITABINE/TENOFOVIR; DIN 02393549; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Jamp Efavirenz/Emtricitabine/Tenofovir · DIN 02519461 Shortage status: active shortage (reported 2026-03-12, estimated to end 2027-06-30, last updated 2026-09-21); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02519461

Check this DIN again

Mylan-Efavirenz/Emtricitabine/Tenofovir · DIN 02461412 Shortage status: active shortage (reported 2024-10-07, last updated 2025-04-14); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461412

Check this DIN again

Teva-Efavirenz/Emtricitabine/Tenofovir · DIN 02393549 Shortage status: active shortage (reported 2025-01-20, last updated 2025-01-23); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02393549

Check this DIN again

Atripla · DIN 02300699 Shortage status: discontinued (2021-12-31, reported by GILEAD SCIENCES, LLC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02300699

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)